Daniel Vaena, MD - West Cancer Center

Dr. Daniel A Vaena

Claim this profile

West Cancer Center

Studies Transitional Cell Carcinoma
Studies Bladder Cancer
7 reported clinical trials
17 drugs studied

Area of expertise

1Transitional Cell Carcinoma
Daniel A Vaena has run 3 trials for Transitional Cell Carcinoma. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Bladder Cancer
Daniel A Vaena has run 3 trials for Bladder Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive

Affiliated Hospitals

Image of trial facility.
The West Clinic, P.C.
Image of trial facility.
West Cancer Center & Research Institute

Clinical Trials Daniel A Vaena is currently running

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3

More about Daniel A Vaena

Clinical Trial Related3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Daniel A Vaena has experience with
  • Nivolumab
  • Docetaxel
  • Pembrolizumab
  • BMS-986258
  • Cetuximab
  • BMS-986315

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Daniel A Vaena specialize in?
Is Daniel A Vaena currently recruiting for clinical trials?
Are there any treatments that Daniel A Vaena has studied deeply?
What is the best way to schedule an appointment with Daniel A Vaena?
What is the office address of Daniel A Vaena?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security